Navigation Links
LUTRONIC® Finalizes Multi-System SPECTRA™ Deal with Unink, a Leading Tattoo Removal Chain in USA
Date:7/31/2013

Fremont, CA (PRWEB) July 31, 2013

LUTRONIC®, a global leader of lasers and therapeutic devices for aesthetic and medical applications, announced today the finalization of a multi-system SPECTRA™ deal with Unink Tattoo Removal, a leading tattoo removal chain in the USA.

Unink chose the Lutronic Spectra, a dual mode Q-switched Nd:YAG laser, because of its versatile and efficacious removal of multi-color tattoo inks. It offers four distinct wavelengths: 1064 nm, 532 nm and delivered via dye handpieces 585 nm and 650 nm. These options can target a wide variety of ink colors, including but not limited to black, red, green, blue and orange. Physicians and patients alike are impressed with the clearance achieved by the Spectra system. The technology behind the Spectra laser makes it truly unique; starting with the top-hat beam profile, which eliminates hotspots and true nanosecond pulse width, the system is developed for consistent outcomes and efficacious treatments.

“We are happy to have the right solution for the Unink Tattoo Removal franchise and are looking forward to many years of successful partnership,” shared Mark Merritt, USA Sales Director at Lutronic. “Our systems are reliable, effective, and backed by an outstanding support team. Ultimately, it is the patients who will truly benefit.”

Unink is a nationwide franchise with multiple locations and aggressive plans for expansion into new markets. By specializing exclusively in tattoo removal, the Unink technicians can focus on providing their patients with the best, most efficient treatment options at affordable prices.

“After a lot of thought and technology evaluation, Unink is proud to partner with Lutronic and choose the Spectra laser for all of our Tattoo removal clinics,” stated Stephen Heusinger, Chief Executive Officer of Unink Tattoo Removal. “Due to our high volume clinics we had to choose a partner that had a very effective system with proven reliability and superior clinical results. When we compared the product, service, training and support of Lutronic with other laser technology options, it became very clear that Lutronic and the Spectra was the right choice.”

About SPECTRA
LUTRONIC’s Dual-pulsed Q-switched Nd:YAG SPECTRA™ laser has been engineered to meet the growing demands of a busy clinic, and includes a variety of efficacious treatment options, customizable parameters, built-in safety and minimized downtimes, all at an affordable price.

With four distinct Q-switched mode wavelengths - 1064 nm, 532 nm, 585 nm, 650 nm, the robust Spectra has the versatility to provide your practice with a wide range of clinical options for treating your patients. Lutronic continually expands its treatment applications; and Spectra is the first Q-switched Nd:YAG laser cleared for the treatment of melasma. The technically advanced Spectra system offers an edge over other lasers and provides enhanced clinical outcomes.

To learn more about the Spectra please visit: http://www.lutronic.com/SPECTRA.

About LUTRONIC
Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 15 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, skin resurfacing, body/facial contouring, chronic pain and more.

With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 130 current and pending patents worldwide. With more than 230 employees worldwide, Lutronic has offices in the US, Korea, China, Japan, and Europe, a worldwide network of distributors, and is ever expanding.

Learn More: http://www.lutronic.com

About UNINK Tattoo Removal
Unink Tattoo Removal is recognized as the fastest growing chain of tattoo removal clinics in the United States. The company is headquartered in Dallas, Texas, and backed by an investment firm with over 15 years of experience in healthcare sector investments. For investor or press information, contact Unink at 855-Ink-Away (855-465-2929), or Stephen Heusinger, CEO at sheusinger(at)unink(dot)com.

Learn more: http://www.uninktattooremoval.com

Contact:
Tracy Evleshin
Global Marketing Communications Director
850 Auburn Ct., Fremont CA 95134

Read the full story at http://www.prweb.com/releases/2013/7/prweb10985957.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lutronic® Announces FDA Clearance for INFINI™, an Ideal Solution for Wrinkle Reduction Through 3-D Volumization
2. Cloud Medical Doctor Software Corporation Finalizes Acquisition of Doctors Network of America and Expands its Medical Billing Services West
3. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
4. Diabetes drug could treat leading cause of blindness
5. Pneumonia and preterm birth complications are the leading causes of childhood death
6. Leading health care quality expert is 2012 AcademyHealth Distinguished Investigator
7. Dr. Edmund Lipskis & Dr. Lynn Lipskis Will be Featured On New National Television Show Entitled: “Leading The Field” World Class Experts Share Their Tips & Advice
8. ACR: Medical imaging study in health affairs incomplete and potentially misleading
9. Poorly-performing hand implants unacceptable says leading medical journal
10. Leading cancer specialists from Europe and beyond recognized at ESMO 2012
11. WSU researchers discover mechanism leading from trichomoniasis to prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... 2016 , ... Mirixa Corporation , a leading healthcare ... patient care services, has announced the promotions of Karen Litsinger to senior vice ... sales. , Litsinger joined Mirixa in 2008 after serving as a partner ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... modes of access for customers and employees that are both engaging and easy ... with Service Smart Technology, the software company revealed today its plans to roll ...
(Date:12/8/2016)... ... , ... California Senate Bill (SB) 863, signed into law in 2012, may ... 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a study ... medical payments per claim in California decreased 4 percent in 2013 and then 3 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... planning services from offices headquartered in Hamilton County, is embarking on a charity ... LuvFurMutts specializes in finding new homes for orphaned or neglected senior dogs in ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... -- Eli Lilly and Company (NYSE: LLY ) ... trial at the 9 th Clinical Trials on ... not meet the primary endpoint in the EXPEDITION3 clinical ... mild dementia due to Alzheimer,s disease (AD), and Lilly ... treatment of mild dementia due to AD. ...
Breaking Medicine Technology: